全文获取类型
收费全文 | 23751篇 |
免费 | 1681篇 |
国内免费 | 168篇 |
专业分类
耳鼻咽喉 | 245篇 |
儿科学 | 777篇 |
妇产科学 | 812篇 |
基础医学 | 2856篇 |
口腔科学 | 399篇 |
临床医学 | 3449篇 |
内科学 | 4414篇 |
皮肤病学 | 453篇 |
神经病学 | 1861篇 |
特种医学 | 455篇 |
外科学 | 2605篇 |
综合类 | 624篇 |
一般理论 | 26篇 |
预防医学 | 2526篇 |
眼科学 | 538篇 |
药学 | 1608篇 |
1篇 | |
中国医学 | 167篇 |
肿瘤学 | 1784篇 |
出版年
2023年 | 145篇 |
2022年 | 243篇 |
2021年 | 602篇 |
2020年 | 423篇 |
2019年 | 579篇 |
2018年 | 608篇 |
2017年 | 461篇 |
2016年 | 544篇 |
2015年 | 648篇 |
2014年 | 859篇 |
2013年 | 1187篇 |
2012年 | 1809篇 |
2011年 | 1944篇 |
2010年 | 1074篇 |
2009年 | 881篇 |
2008年 | 1590篇 |
2007年 | 1671篇 |
2006年 | 1496篇 |
2005年 | 1562篇 |
2004年 | 1473篇 |
2003年 | 1382篇 |
2002年 | 1136篇 |
2001年 | 332篇 |
2000年 | 290篇 |
1999年 | 223篇 |
1998年 | 220篇 |
1997年 | 215篇 |
1996年 | 157篇 |
1995年 | 124篇 |
1994年 | 126篇 |
1993年 | 112篇 |
1992年 | 145篇 |
1991年 | 140篇 |
1990年 | 125篇 |
1989年 | 104篇 |
1988年 | 81篇 |
1987年 | 62篇 |
1986年 | 84篇 |
1985年 | 74篇 |
1984年 | 83篇 |
1983年 | 73篇 |
1982年 | 62篇 |
1981年 | 51篇 |
1980年 | 66篇 |
1979年 | 52篇 |
1978年 | 51篇 |
1977年 | 39篇 |
1976年 | 27篇 |
1974年 | 29篇 |
1972年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献3.
4.
5.
Eric S. Zhou Larissa Nekhlyudov Sharon L. Bober 《Translational andrology and urology》2015,4(2):218-231
There is a large and growing population of long-term cancer survivors. Primary care physicians (PCPs) are playing an increasingly greater role in the care of these patients across the continuum of cancer survivorship. In this role, PCPs are faced with the responsibility of managing a range of medical and psychosocial late effects of cancer treatment. In particular, the sexual side effects of treatment which are common and have significant impact on quality of life for the cancer survivor, often go unaddressed. This is an area of clinical care and research that has received increasing attention, highlighted by the presentation of this special issue on Cancer and Sexual Health. The aims of this review are 3-fold. First, we seek to overview common presentations of sexual dysfunction related to major cancer diagnoses in order to give the PCP a sense of the medical issues that the survivor may present with. Barriers to communication about sexual health issues between patient/PCPs in order are also described in order to emphasize the importance of PCPs initiating this important conversation. Next, we provide strategies and resources to help guide the PCP in the management of sexual dysfunction in cancer survivors. Finally, we discuss case examples of survivorship sexual health issues and highlight the role that a PCP can play in each of these case examples. 相似文献
6.
7.
8.
Bernard Natukunda Grace Ndeezi Lay See Er Francis Bajunirwe Gayle Teramura Meghan Delaney 《ISBT科学丛刊》2019,14(4):366-373
9.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages 下载免费PDF全文
10.